

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 May 2011 (26.05.2011)

PCT

(10) International Publication Number
WO 2011/063264 A1

(51) International Patent Classification:
A61K 47/42 (2006.01)

(21) International Application Number:
PCT/US2010/057480

(22) International Filing Date:
19 November 2010 (19.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/263,213 20 November 2009 (20.11.2009) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF CHICAGO** [US/US]; 5801 S. Ellis, Chicago, IL 60637 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **COLLIER, Joel, H.** [US/US]; Office Of Technology & Intellectual Property, 5555 S Woodlawn, Suite 300, Chicago, IL 60637 (US).

(74) Agent: **LANDRUM, Charles, P.**; Fulbright & Jaworski L.L.P., 600 Congress Ave., Suite 2400, Austin, TX 78701 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND COMPOSITIONS RELATED TO IMMUNOGENIC FIBRILS

(57) Abstract: Embodiments of the invention are directed to fibrillar adjuvants. Epitopes assembled into nanofibers by a short synthetic fibrillization domain elicited high antibody titers in the absence of any adjuvant.



WO 2011/063264 A1

DESCRIPTION

METHODS AND COMPOSITIONS RELATED TO IMMUNOGENIC FIBRILS

[0001] This application claims priority to U.S. Provisional Patent Application serial number 61/263,213 filed November 20, 2009, which is incorporated herein by reference in its entirety.

- 5 [0002] This invention was made with government support under DE017703 and EB009701 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

I. FIELD OF THE INVENTION

- 10 [0003] Embodiments of this invention are directed generally to biology, medicine, and immunology. Certain aspects are directed to immunogenic fibrils and their use in inducing an immune response.

II. BACKGROUND

- 15 [0004] The development of vaccines and other immunotherapies has been challenged by imprecise antigen display and the use of heterogeneous immune adjuvants whose mechanisms of action are complex and incompletely understood. Synthetic peptides are useful as antigens because their precise chemical definition allows one to specify the exact epitopes against which an immune response is to be raised. However, peptides are poorly immunogenic by themselves and require co-administration with strong adjuvants, a process that sacrifices the
- 20 chemical definition that peptides possess initially and complicates their development and regulatory approval Lambrecht *et al.*, 2009; Marrack *et al.*, 2009; Purcell *et al.*, 2007). Although several adjuvants have been investigated for peptide immunotherapies to date, current strategies such as particulates (Marrack *et al.*, 2009; Wendorf *et al.*, 2006), oil emulsions (Daftarian *et al.*, 2006), toll-like receptor ligands (Ishii and Akira, 2007), ISCOMs
- 25 (Maraskovsky *et al.*, 2009), and other biologically sourced materials (McSorley *et al.*, 2002; Sun *et al.*, 2009) utilize chemically or structurally heterogeneous materials, making characterization and mechanistic understanding challenging. This situation has motivated the pursuit of self-adjuvanting or adjuvant-free systems (Bettahi *et al.*, 2009; Cao *et al.*, 2008; Toth *et al.*, 2008).

[0005] There remains a need for additional immunogenic compositions to induce immune responses for treating microbial infection and other pathogenic conditions.

SUMMARY OF THE INVENTION

[0006] Strong antibody responses have been observed in mice without the co-administration of any additional adjuvant by non-covalently assembling a T and B cell epitope peptide into nanofibers using a short C-terminal peptide extension. The inventors have discovered that self-assembling peptides are useful as chemically defined adjuvants. In physiological conditions, these peptides self-assembled into long, unbranched fibrils that displayed the epitope on their surfaces. IgG1, IgG2a, and IgG3 were raised against epitope-bearing fibrils in levels similar to the epitope peptide delivered in complete Freund's adjuvant (CFA), and IgM production was even greater for the self-assembled epitope. This response was dependent on self-assembly, and the self-assembling sequence was not immunogenic by itself, even when delivered in CFA.

[0007] Certain embodiments of the invention are directed to immunogenic compositions comprising a peptide fibril coupled to a plurality of antigens. In certain aspects, the peptide fibril comprises a plurality of self-assembling peptides. The peptide fibril can have a length of at least 0.25, 0.5, 1, 10, 50 to 10, 25, 50, 100 μm , including all values and ranges there between. In certain aspects, the peptide fibril has a molecular weight of at least 1,000, 5,000, 10,000, 100,000 da to 1×10^6 , 1×10^7 , 7×10^8 da, including all values and ranges there between. In other aspects the self-assembling peptides form a beta-sheet rich fibril. In further aspects, the self-assembling peptide comprises an amino acid sequence of QQKFQFQFEQQ (SEQ ID NO:1; KFQFQFE (SEQ ID NO:2); QQRFFQFQFEQQ (SEQ ID NO:3); QQRFFQWQFEQQ (SEQ ID NO:4); FEFEFKFKFEFEFKFK (SEQ ID NO:5); QQRFEWEFEQQ (SEQ ID NO:6); QQXFXWXFQQQ (SEQ ID NO:7) (Where X denotes ornithine); FKFEFKFEFKFE (SEQ ID NO:8); FKFKFKFKFKFK (SEQ ID NO:9); AEAKAEAKAEAKAEAK (SEQ ID NO:10); AEAEAKAKAEAEAKAK (SEQ ID NO:11); AEAEAEAEAKAKAKAK (SEQ ID NO:12); RADARADARADARADA (SEQ ID NO:13); RARADADARARADADA (SEQ ID NO:14); SGRGYBLGGQGAGAAAAAGGAGQGGYGGLGSQG (SEQ ID NO:15); EWEXEXEXEX (SEQ ID NO:16) (Where X = V, A, S, or P); WKXKXKXKXK (SEQ ID NO:17) (Where X = V, A, S, or P); KWKVKKVKVKVKVKV (SEQ ID NO:18); LLLLKKKKKKKKLLLL (SEQ ID NO:19); VKVKVKVKVDPPTKVVKVKVKV (SEQ ID NO:20);

VKVKVKVKVDPPTKVTKVKV (SEQ ID NO:21; KVKVKVKVKDPPSVKVKVKVK (SEQ ID NO:22; or VKVKVKVKVDPPSKVKVKVKV (SEQ ID NO:23); VKVKVKTKVDPPTKVTKVKV (SEQ ID NO:24). In certain aspects, the self-assembling peptide is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 to 15, 20, 25, 30, 35, 40 amino acids in length, including all values and ranges there between. In certain aspects, more than one self-assembling peptide is present in a peptide fibril. In certain aspects the self assembling peptides comprise an immunogenic peptide or an antigen. In certain aspects the antigen(s) are polypeptides. In a further aspect the polypeptides are covalently coupled to the peptide fibril. In still a further aspect the polypeptides are covalently coupled to the peptide fibril via a cutinase polypeptide.

[0008] In a further aspect, the antigen is covalently coupled to the self-assembling peptide. In a further aspect, the antigen is covalently coupled to the N and/or C terminus of the self-assembling peptide. In still further aspects, the antigen is covalently coupled to the carboxy terminus of the self-assembling peptide. In certain aspects the ratio of antigen to self-assembling peptide is 1:1000, 1:100: 1:10, or 1:1, including all values and ranges there between. Antigens can be microbial antigens, such as viral, fungal, or bacterial; or therapeutic antigens such as antigens associated with cancerous cells or growths, or autoimmune disorders. In certain aspects, the antigens are peptides, lipids, carbohydrates, or other immunogenic molecules. In a further aspect, the peptides are 5, 10, 15, 20 to 15, 20, 30, 40 amino acids in length, including all values and ranges there between. The antigens can be T cell and/or B cell epitopes.

[0009] Further embodiments include self-assembling antigens comprising an antigen coupled to a fibril-forming peptide.

[0010] Certain embodiments are directed to methods of inducing an immune response comprising administering an antigenic fibril, comprising a self-assembling peptide coupled to an antigen, in an amount sufficient to induce an immune response.

[0011] Further embodiments are directed to methods of treating a subject having or at risk of developing a microbial infection, cancer, or other condition that can be treated by inducing an immune response comprising administering to the subject an effective amount of a composition described herein.

[0012] As used herein, the term “antigen” is a molecule capable of being bound by an antibody or T-cell receptor. An antigen is additionally capable of inducing a humoral immune response and/or cellular immune response leading to the production of B- and/or T-lymphocytes. The structural aspect of an antigen that gives rise to a biological response is referred to herein as an “antigenic determinant.” B-lymphocytes respond to foreign antigenic determinants via antibody production, whereas T-lymphocytes are the mediator of cellular immunity. Thus, antigenic determinants or epitopes are those parts of an antigen that are recognized by antibodies, or in the context of an MHC, by T-cell receptors. An antigenic determinant need not be a contiguous sequence or segment of protein and may include various sequences that are not immediately adjacent to one another.

[0013] Other embodiments of the invention are discussed throughout this application. Any embodiment discussed with respect to one aspect of the invention applies to other aspects of the invention as well and vice versa. The embodiments in the Example section are understood to be embodiments of the invention that are applicable to all aspects of the invention.

[0014] The terms “inhibiting,” “reducing,” or “prevention,” or any variation of these terms, when used in the claims and/or the specification includes any measurable decrease or complete inhibition to achieve a desired result.

[0015] The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

[0016] It is contemplated that any embodiment discussed herein can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions and kits of the invention can be used to achieve methods of the invention.

[0017] Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

[0018] The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.” It is also contemplated that anything listed using the term “or” may also be specifically excluded.

[0019] As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0020] Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

[0021] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0022] **FIGs. 1A-1B** Schematic (A) and sequences (B) of epitope-bearing self-assembling peptides. The Q11 domain assembles into fibrillar aggregates, displaying the epitope sequence at the end of a flexible spacer.

[0023] **FIGs. 2A-2F** Q11-based peptides self-assembled into β -sheet fibrils that displayed functional epitopes on their surfaces. Q11 (A) self-assembled into long, unbranched fibrils that did not bind streptavidin-gold (B). O-Q11 (C) also formed long, unbranched fibrils, and biotin-O-Q11 bound streptavidin-gold (D), indicating availability of the N-terminus on the fibril surface. O-Q11 possessed a predominant β -sheet structure by CD (E). OVA antisera reacted similarly to ELISA plates coated with OVA or O-Q11 (F). Each point represents one mouse's serum; bars represent the mean. * $p < 0.01$ compared to OVA coat/OVA in PBS injection, by ANOVA with Tukey HSD post-hoc testing. n.s., not statistically different.

[0024] **FIGs. 3A-3D** Fibrillization by the Q11 domain strongly adjuvanted IgG responses to OVA. Similar titers of total IgG were raised against O-Q11 delivered in PBS and OVA delivered in CFA, whereas Q11 or OVA delivered in PBS did not elicit a response (A). Q11

was non-immunogenic even in CFA, whereas CFA increased IgG titers for O-Q11 (B). O-Q11 antisera were strongly cross-reactive to OVA-coated ELISA plates and showed a small amount of reactivity to Q11-coated plates that was not statistically significant (C). The adjuvant activity of Q11 was entirely dependent on covalent conjugation between the fibrillizing domain and epitope domain, as mixtures of Q11 and OVA did not raise any OVA-specific IgG (D). Each point represents one mouse; bars represent the mean. * $p < 0.01$ by ANOVA with Tukey HSD post-hoc testing, compared with OVA in PBS, or between groups as indicated.

[0025] **FIG. 4** Antibody isotypes in sera from mice immunized with peptides. Each point represents one mouse; bars represent the mean. * $p < 0.01$ compared with OVA delivered in PBS by ANOVA with Tukey HSD post-hoc test. § $p < 0.05$ as indicated.

[0026] **FIGs. 5A-5C** IFN- γ , IL-2, and IL-4 production in peptide-challenged (triangles) and unchallenged (circles) splenocyte cultures. Each point represents one mouse; bars represent the mean. * $p < 0.01$ compared with corresponding unchallenged control, by ANOVA with Tukey HSD post-hoc test.

[0027] **FIG. 6** Shows total IgG ELISA absorbance values for serially diluted serum from individual mice, corresponding to the titer calculations shown in FIG. 5. Each line represents one mouse. Mice receiving O-Q11 in PBS, OVA in CFA, Q11, and OVA in PBS are shown. The inset shows an expanded scale, for visualizing the low absorbance values of the Q11 and negative control mice.

[0028] **FIG. 7** Total IgG antibodies by mice immunized with GFP-cutinase-phosphonate-Q11 fibrils, cutinase-GFP emulsified in CFA, or cutinase-GFP in PBS.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The development of vaccines and other immunotherapies has been challenged by imprecise antigen display and the use of heterogeneous immune adjuvants whose mechanisms of action are complex and incompletely understood. Synthetic peptides are useful as antigens because their precise chemical definition allows one to specify the exact epitopes against which an immune response is to be raised. However, peptides are poorly immunogenic by themselves and require co-administration with strong adjuvants, a process that sacrifices the chemical definition that peptides possess initially and complicates their development and

regulatory approval (Lambrecht *et al.*, 2009; Marrack *et al.*, 2009; Purcell *et al.*, 2007). Although several adjuvants have been investigated for peptide immunotherapies to date, current strategies such as particulates (Marrack *et al.*, 2009; Wendorf *et al.*, 2006), oil emulsions (Daftarian *et al.*, 2006), toll-like receptor ligands (Ishii and Akira, 2007), ISCOMs (Maraskovsky *et al.*, 2009), and other biologically sourced materials (McSorley *et al.*, 2002; Sun *et al.*, 2009) utilize chemically or structurally heterogeneous materials, making characterization and mechanistic understanding challenging. This situation has motivated the pursuit of self-adjuvanting or adjuvant-free systems (Bettahi *et al.*, 2009; Cao *et al.*, 2008; Toth *et al.*, 2008).

[0030] A broad goal in the field of biomaterials is to produce synthetic scaffolds capable of presenting multiple cell-interactive components in spatially resolved networks (Lutolf and Hubbell, 2005; Place *et al.*, 2009). To accomplish this, supramolecular self-assembly is rapidly becoming a synthetic method of choice (Silva *et al.*, 2004; Jung *et al.*, 2009; Collier, 2008). One strategy that has received attention recently is based on fibrillized peptides, peptidomimetics, and peptide derivatives, which are being explored for a variety of biomedical and biotechnological applications, most notably as scaffolds for regenerative medicine (Davis *et al.*, 2005; Tysseling-Mattiace, 2008) and defined matrices for cell culture (Genove *et al.*, 2005; Horii *et al.*, 2007). In these applications, self-assembled materials provide several advantages, including multifunctionality, multivalency, synthetic definition, molecular specificity, and control over the nanoscale positioning of ligands and other biomolecular features (Collier, 2008). Self-assembled, multi-component matrices for cell culture using a short fibrillizing peptide, Q11 (Ac-QQKFQFQFEQQ-Am) (SEQ ID NO:1) have been described (Jung *et al.*, 2009; Collier, 2008; Collier and Messersmith, 2003; Jung *et al.*, 2008). This peptide, like other previously reported short fibrillizing peptides (Horii *et al.*, 2007; Holmes *et al.*, 2000; Aggeli *et al.*, 1997; Gras *et al.*, 2008), β -hairpins (Schneider *et al.*, 2002), peptide-amphiphiles (Tysseling-Mattiace, 2008; Hartgerink *et al.*, 2001), and peptide derivatives (Zhou *et al.*, 2009), self-assembles in salt-containing aqueous environments to form networks of β -sheet-rich nanofibers. It is also capable of displaying functional amino acid sequences or chemical groups on the surface of its self-assembled fibers. For example, adding cell-binding amino acid sequences to the N-terminus of Q11 leads to self-assembled fibrils that functionally present the cell-binding peptides on their surfaces (Jung *et al.*, 2009). Q11 with an N-terminal cysteine and a C-terminal thioester can undergo native chemical ligation after assembly, which can be used to stiffen the fibrillar network (Jung *et al.*, 2008).

These peptides can also be mixed to display precise combinations of different ligands (Jung *et al.*, 2009).

[0031] During initial development as scaffolds for regenerative medicine, Q11 and other self-assembling peptide-based materials have been found to be minimally immunogenic. In previous work, Q11 and Q11 with N-terminal cell-binding RGDS sequences elicited little to no antibody responses in mice (Jung *et al.*, 2009). Negligible tissue responses were also observed for β -sheet fibrillizing RAD16-II peptide assemblies injected within rat (Hsieh *et al.*, 2006) or mouse (Davis *et al.*, 2005) myocardium. Low antibody titers have also been reported in rabbits and goats for RAD16 peptides (Holmes *et al.*, 2000). One study observed an inflammatory response to RAD16 peptides in rats, but the causes were not known (Dubois *et al.*, 2008). The minimal immunogenicity of these materials observed to date is clearly advantageous for applications in regenerative medicine, but previous work has focused largely on amino acid sequences that are already found in endogenous proteins, for example the RGDS cell-binding sequence from fibronectin (Jung *et al.*, 2009; Guler *et al.*, 2006). Because of this, strong epitopes have effectively been avoided. In the present work, it was sought to determine the extent to which the previously observed low immunogenicity also applied to peptide sequences containing stronger epitopes. The results show a surprisingly robust antibody response generated against a self-assembled B and T cell epitope, indicating that self-assembled peptides can serve as powerful chemically defined adjuvants.

I. SELF-ASSEMBLING PEPTIDES

[0032] Certain aspects of the invention include self-assembling peptides. As used herein, the term "self-assembling peptide" refers to peptides that are able to spontaneously associate and form stable structures. In one embodiment, a self-assembling peptide of the present invention comprises an amino acid sequence of QQKFQFQFEQQ; KFQFQFE; QQRFFQFQFEQQ; QQRFFQWQFEQQ; FEFEFKFKFEFEFKFK; QQRFEWEFEQQ; QQXFXWQFQQQ (Where X denotes ornithine); FKFEFKFEFKFE; FKFQFKFQFKFQ; AEAKAEAKAEAKAEAK; AEAEAKAKAEAEAKAK; AEAEAEAEAKAKAKAK; RADARADARADARADA; RARADADARARADADA; SGRGYBLGGQGAGAAAAAGGAGQGGYGGLGSQG; EWEXEXEXEX (Where X = V, A, S, or P); WKXKXKXKXK (Where X = V, A, S, or P); KWKVVKVKVKVKVKVK; LLLLKKKKKKKKLLLL; VKVKVKVKVDPPTKVVKVKVKV; VKVKVKVKVDPPTKVTKVKVKV; KVKVKVKVKDPPSVKVKVKVKV;

VKVKVKVKVDPPSKVKVKVKV; VKVKVKTKVDPPTKVKTKVKV or conservatively modified variants thereof. Self-assembling peptides may further comprise other compounds, for example, immunogenic peptides.

5 [0033] Certain peptides that comprise of alternating hydrophilic and hydrophobic amino acids self-assemble to form an exceedingly stable beta-sheet macroscopic scaffold (U.S. Pat. Nos. 5,955,343 and 5,670,483, each of which is incorporated herein by reference).

Many self-complementary peptides have identical compositions and length; such as EAK16, KAE16, RAD16, RAE16, and KAD16; have been analyzed previously (Table 1).

Table. 1

Representative Self-Assembling peptides				
Name	Sequence (n-->c)	SEQ ID NO:	Modulus	Structure
RADA16-I	n-RADARADARADARADA-c	29	I	β
RGDA16-I	n-RADARGDARADARGDA-c	30	I	r.c.
RADA8-I	n-RADARADA-c	31	I	r.c.
RAD16-II	n-RARADADARARADADA-c	32	II	β
RAD8-II	n-RARADADA-c	33	II	r.c.
EAKA16-I	n-AEAKAEAKAEAKAEAK-c	34	I	β
EAKA8-I	n-AEAKAEAK-c	35	I	r.c.
RAEA16-I	n-RAEARAEARAEARAEA-c	36	I	β
RAEA8-I	n-RAEARAEA-c	37	I	r.c.
KADA16-I	n-KADAKADAKADAKADA-c	38	I	β
KADA8-I	n-KADAKADA-c	39	I	r.c.
EAH16-II	n-AEAEAHAAEAEAHAAHA-c	40	II	β
EAH8-II	n-AEAEAHAAHA-c	41	II	r.c.
EFK16-II	n-FEFEFKFKFEFEFKFK-c	42	II	β
EFK8-II	n-FEFKFEFK-c	43	I	β
ELK16-II	n-LELELKLKLELELKLK-c	44	II	β
ELK8-II	n-LELELKLK-c	45	II	r.c.
EAK16-II	n-AEAEAKAKAEAEAKAK-c	46	II	β
EAK12	n-AEAEAEAEAKAK-c	47	IV/II	α/β
EAK8-II	n-AEAEAKAK-c	48	II	r.c.
KAE16-IV	n-KAKAKAKAEAEAEAE-c	49	IV	β
EAK16-IV	n-AEAEAEAEAKAKAKAK-c	50	IV	β
RAD16-IV	n-RARARARADADADADA-c	51	IV	β
DAR16-IV	n-ADADADADARARARAR-c	52	IV	α/β
DAR16-IV*	n-DADADADARARARARA-c	53	IV	α/β
DAR32-IV	n-(ADADADADARARARAR)-c	52	IV	α/β
EHK16	n-HEHEHKHKHEHEHKHK-c	54	N/A	r.c.
EKH8-I	n-HEHEHKHK-c	55	N/A	r.c.
VE20*	n-VEVEVEVEVEVEVEVEVEVE-c	56	N/A	β
RF20*	n-RFRFRFRFRFRFRFRFRFRF-c	57	N/A	β

β denotes beta-sheet;

α denotes alpha-helix;

r.c. denotes random coil;

5 N/A denotes not applicable.

*Both VE20 and RF20 form a beta-sheet when they are incubated in a solution containing NaCl; however, they do not self-assemble to form macroscopic scaffolds.

[0034] The peptides described herein can be chemically synthesized using standard chemical synthesis techniques. In some embodiments the peptides are chemically synthesized by any of a number of fluid or solid phase peptide synthesis techniques known to those of skill in the art. Solid phase synthesis in which the C-terminal amino acid of the sequence is attached to an insoluble support followed by sequential addition of the remaining amino acids in the sequence is a preferred method for the chemical synthesis of the polypeptides of this

invention. Techniques for solid phase synthesis are well known to those of skill in the art and are described, for example, by Barany and Merrifield (1963) Solid-Phase Peptide Synthesis; pp. 3-284 in The Peptides: Analysis, Synthesis, Biology. Vol. 2: Special Methods in Peptide Synthesis, Part A.; Merrifield et al. (1963) J. Am. Chem. Soc., 85: 2149-2156, and Stewart et al. (1984) Solid Phase Peptide Synthesis, 2nd ed. Pierce Chem. Co., Rockford, Ill

II. ANTIGENS

[0035] The term "antigen" as used herein refers to a molecule against which a subject can initiate a humoral and/or cellular immune response. Antigens can be any type of biologic molecule including, for example, simple intermediary metabolites, sugars, lipids, and hormones as well as macromolecules such as complex carbohydrates, phospholipids, nucleic acids and proteins. Common categories of antigens include, but are not limited to, viral antigens, bacterial antigens, fungal antigens, protozoa and other parasitic antigens, tumor antigens, antigens involved in autoimmune disease, allergy and graft rejection, and other miscellaneous antigens. In certain compositions and methods of the invention, the antigen is a peptide.

[0036] **Viral Antigens.** Examples of viral antigens include, but are not limited to, retroviral antigens such as retroviral antigens from the human immunodeficiency virus (HIV) antigens such as gene products of the gag, pol, and env genes, the Nef protein, reverse transcriptase, and other HIV components; hepatitis viral antigens such as the S, M, and L proteins of hepatitis B virus, the pre-S antigen of hepatitis B virus, and other hepatitis, e.g., hepatitis A, B. and C, viral components such as hepatitis C viral RNA; influenza viral antigens such as hemagglutinin and neuraminidase and other influenza viral components; measles viral antigens such as the measles virus fusion protein and other measles virus components; rubella viral antigens such as proteins E1 and E2 and other rubella virus components; rotaviral antigens such as VP7sc and other rotaviral components; cytomegaloviral antigens such as envelope glycoprotein B and other cytomegaloviral antigen components; respiratory syncytial viral antigens such as the RSV fusion protein, the M2 protein and other respiratory syncytial viral antigen components; herpes simplex viral antigens such as immediate early proteins, glycoprotein D, and other herpes simplex viral antigen components; varicella zoster viral antigens such as gpI, gpII, and other varicella zoster viral antigen components; Japanese encephalitis viral antigens such as proteins E, M-E, M-E-NS 1, NS 1, NS 1-NS2A, 80% E, and other Japanese encephalitis viral antigen components; rabies viral antigens such as rabies

glycoprotein, rabies nucleoprotein and other rabies viral antigen components. See Fundamental Virology, Second Edition, e's. Fields, B. N. and Knipe, D. M. (Raven Press, New York, 1991) for additional examples of viral antigens.

[0037] **Bacterial Antigens.** Bacterial antigens which can be used in the compositions and methods of the invention include, but are not limited to, pertussis bacterial antigens such as pertussis toxin, filamentous hemagglutinin, pertactin, FIM2, FIM3, adenylate cyclase and other pertussis bacterial antigen components; diphtheria bacterial antigens such as diphtheria toxin or toxoid and other diphtheria bacterial antigen components; tetanus bacterial antigens such as tetanus toxin or toxoid and other tetanus bacterial antigen components; streptococcal bacterial antigens such as M proteins and other streptococcal bacterial antigen components; gram-negative bacilli bacterial antigens such as lipopolysaccharides and other gram-negative bacterial antigen components; Mycobacterium tuberculosis bacterial antigens such as mycolic acid, heat shock protein 65 (HSP65), the 30 kDa major secreted protein, antigen 85A and other mycobacterial antigen components; Helicobacter pylori bacterial antigen components; pneumococcal bacterial antigens such as pneumolysin, pneumococcal capsular polysaccharides and other pneumococcal bacterial antigen components; hemophilus influenza bacterial antigens such as capsular polysaccharides and other hemophilus influenza bacterial antigen components; anthrax bacterial antigens such as anthrax protective antigen and other anthrax bacterial antigen components; rickettsiae bacterial antigens such as romps and other rickettsiae bacterial antigen component. Also included with the bacterial antigens described herein are any other bacterial, mycobacterial, mycoplasmal, rickettsial, or chlamydial antigens.

[0038] **Fungal Antigens.** Fungal antigens which can be used in the compositions and methods of the invention include, but are not limited to, Candida fungal antigen components; histoplasma fungal antigens such as heat shock protein 60 (HSP60) and other histoplasma fungal antigen components; cryptococcal fungal antigens such as capsular polysaccharides and other cryptococcal fungal antigen components; coccidioides fungal antigens such as spherule antigens and other coccidioides fungal antigen components; and tinea fungal antigens such as trichophytin and other coccidioides fungal antigen components.

[0039] **Parasite Antigens.** Examples of protozoa and other parasitic antigens include, but are not limited to, plasmodium falciparum antigens such as merozoite surface antigens, sporozoite surface antigens, circumsporozoite antigens, gametocyte/gamete surface antigens,

blood-stage antigen pf 1 55/RESA and other plasmodial antigen components; toxoplasma antigens such as SAG-1, p30 and other toxoplasma antigen components; schistosomae antigens such as glutathione-S-transferase, paramyosin, and other schistosomal antigen components; leishmania major and other leishmaniae antigens such as gp63,
5 lipophosphoglycan and its associated protein and other leishmanial antigen components; and trypanosoma cruzi antigens such as the 75-77 kDa antigen, the 56 kDa antigen and other trypanosomal antigen components.

[0040] **Tumor antigens.** Tumor antigens which can be used in the compositions and methods of the invention include, but are not limited to, telomerase components; multidrug
10 resistance proteins such as P-glycoprotein; MAGE-1, alpha fetoprotein, carcinoembryonic antigen, mutant p53, immunoglobulins of B-cell derived malignancies, fusion polypeptides expressed from genes that have been juxtaposed by chromosomal translocations, human chorionic gonadotropin, calcitonin, tyrosinase, papillomavirus antigens, gangliosides or other carbohydrate-containing components of melanoma or other tumor cells. It is contemplated by
15 the invention that antigens from any type of tumor cell can be used in the compositions and methods described herein.

[0041] **Antigens Relating to Autoimmunity.** Antigens involved in autoimmune diseases, allergy, and graft rejection can be used in the compositions and methods of the invention. For example, an antigen involved in any one or more of the following autoimmune diseases or
20 disorders can be used in the present invention: diabetes mellitus, arthritis (including rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, autoimmune thyroiditis, dermatitis (including atopic dermatitis and eczematous dermatitis), psoriasis, Sjogren's Syndrome, including keratoconjunctivitis sicca secondary to Sjogren's Syndrome, alopecia areata, allergic
25 responses due to arthropod bite reactions, Crohn's disease, aphthous ulcer, iritis, conjunctivitis, keratoconjunctivitis, ulcerative colitis, asthma, allergic asthma, cutaneous lupus erythematosus, scleroderma, vaginitis, proctitis, drug eruptions, leprosy reversal reactions, erythema nodosum leprosum, autoimmune uveitis, allergic encephalomyelitis, acute necrotizing hemorrhagic encephalopathy, idiopathic bilateral progressive sensorineural
30 hearing loss, aplastic anemia, pure red cell anemia, idiopathic thrombocytopenia, polychondritis, Wegener's granulomatosis, chronic active hepatitis, Stevens-Johnson syndrome, idiopathic sprue, lichen planus, Crohn's disease, Graves ophthalmopathy, sarcoidosis, primary biliary cirrhosis, uveitis posterior, and interstitial lung fibrosis. Examples

of antigens involved in autoimmune disease include glutamic acid decarboxylase 65 (GAD 65), native DNA, myelin basic protein, myelin proteolipid protein, acetylcholine receptor components, thyroglobulin, and the thyroid stimulating hormone (TSH) receptor. Examples of antigens involved in allergy include pollen antigens such as Japanese cedar pollen antigens, ragweed pollen antigens, rye grass pollen antigens, animal derived antigens such as dust mite antigens and feline antigens, histocompatibility antigens, and penicillin and other therapeutic drugs. Examples of antigens involved in graft rejection include antigenic components of the graft to be transplanted into the graft recipient such as heart, lung, liver, pancreas, kidney, and neural graft components. An antigen can also be an altered peptide ligand useful in treating an autoimmune disease.

[0042] Examples of miscellaneous antigens which can be used in the compositions and methods of the invention include endogenous hormones such as luteinizing hormone, follicular stimulating hormone, testosterone, growth hormone, prolactin, and other hormones, drugs of addiction such as cocaine and heroin, and idiotypic fragments of antigen receptors such as Fab-containing portions of an anti-leptin receptor antibody.

III. PHARMACEUTICAL COMPOSITIONS

[0043] The present invention includes methods for preventing or ameliorating microbial infections. As such, the invention contemplates vaccines and therapeutics for use in active immunization of subjects. Immunogenic compositions can include a peptide fibril coupled to a plurality of antigens, "fibril complex."

[0044] The preparation of vaccines that contain polypeptide or peptide sequence(s) as active ingredients is generally well understood in the art, as exemplified by U.S. Patents 4,608,251; 4,601,903; 4,599,231; 4,599,230; 4,596,792; and 4,578,770, all of which are incorporated herein by reference. Typically, such vaccines are prepared as injectables either as liquid solutions or suspensions: solid forms suitable for solution in or suspension in liquid prior to injection may also be prepared. The preparation may also be emulsified. The active immunogenic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the vaccine may contain amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants that enhance the effectiveness of the vaccines. In specific

embodiments, vaccines are formulated with a combination of substances, as described in U.S. Patents 6,793,923 and 6,733,754, which are incorporated herein by reference.

[0045] Vaccines and therapeutics may be conventionally administered parenterally, by injection, for example, either subcutaneously or intramuscularly. Additional formulations which are suitable for other modes of administration include suppositories and, in some cases, oral formulations. For suppositories, traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides: such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10%, preferably about 1% to about 2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain about 10% to about 95% of active ingredient, preferably about 25% to about 70%.

[0046] The compositions described herein may be formulated into a pharmaceutical composition as neutral or salt forms. Pharmaceutically-acceptable salts include the acid addition salts (formed with the free amino groups of the peptide) and those that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.

[0047] Typically, compositions are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective and immunogenic. The quantity to be administered depends on the subject to be treated, including the capacity of the individual's immune system to synthesize antibodies and the degree of protection desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are of the order of several hundred micrograms active ingredient per vaccination. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by subsequent inoculations or other administrations.

[0048] The manner of application may be varied widely. Any of the conventional methods for administration of a vaccine are applicable. These are believed to include oral application on a solid physiologically acceptable base or in a physiologically acceptable dispersion, parenterally, by injection and the like. The dosage of the vaccine will depend on the route of administration and will vary according to the size and health of the subject.

[0049] The compositions and related methods of the present invention, particularly administration of a peptide fibril/antigen complex may also be used in combination with the administration of traditional therapies. These include, but are not limited to, the administration of antibiotics such as streptomycin, ciprofloxacin, doxycycline, gentamycin, chloramphenicol, trimethoprim, sulfamethoxazole, ampicillin, tetracycline or various combinations of antibiotics.

[0050] In one aspect, it is contemplated that a peptide fibril/antigen vaccine and/or therapy is used in conjunction with antibacterial treatment. Alternatively, the therapy may precede or follow the other agent treatment by intervals ranging from minutes to weeks. In embodiments where the other agents and/or a proteins is administered separately, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent and antigenic composition would still be able to exert an advantageously combined effect on the subject. In such instances, it is contemplated that one may administer both modalities within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it may be desirable to extend the time period for administration significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

[0051] Various combinations may be employed, for example antibiotic therapy is "A" and the immunogenic composition is "B":

[0052] A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B B/A/B/B

[0053] B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A B/B/A/A

[0054] B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A A/A/B/A

[0055] Administration of the immunogenic compositions of the present invention to a patient/subject will follow general protocols for the administration of such compounds, taking into account the toxicity, if any. It is expected that the treatment cycles would be repeated as

necessary. It also is contemplated that various standard therapies, such as hydration, may be applied in combination with the described therapy.

[0056] In some embodiments, pharmaceutical compositions are administered to a subject. Different aspects of the present invention involve administering an effective amount of a composition to a subject. In some embodiments of the present invention, immunogenic compositions may be administered to the patient to protect against infection by one or more microbial pathogens. Additionally, such compounds can be administered in combination with an antibiotic or other known anti-microbial therapy. Such compositions will generally be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.

[0057] The phrases “pharmaceutically acceptable” or “pharmacologically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic, or other untoward reaction when administered to an animal, or human. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in immunogenic and therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-cancer agents, can also be incorporated into the compositions.

[0058] In addition to the compounds formulated for parenteral administration, such as those for intravenous or intramuscular injection, other pharmaceutically acceptable forms include, *e.g.*, tablets or other solids for oral administration; time release capsules; and any other form currently used, including creams, lotions, mouthwashes, inhalants and the like.

[0059] The active compounds of the present invention can be formulated for parenteral administration, *e.g.*, formulated for injection via the intravenous, intramuscular, subcutaneous, or even intraperitoneal routes. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and, the preparations can also be emulsified.

[0060] Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as

hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0061] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that it may be easily injected. It also should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[0062] The proteinaceous compositions may be formulated into a neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.

[0063] The carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0064] Administration of the compositions according to the present invention will typically be via any common route. This includes, but is not limited to oral, nasal, or buccal administration. Alternatively, administration may be by orthotopic, intradermal,

subcutaneous, intramuscular, intraperitoneal, intranasal, or intravenous injection. In certain embodiments, a vaccine composition may be inhaled (*e.g.*, U.S. Patent 6,651,655, which is specifically incorporated by reference). Such compositions would normally be administered as pharmaceutically acceptable compositions that include physiologically acceptable carriers, buffers or other excipients.

[0065] For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage could be dissolved in isotonic NaCl solution and either added to hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, Remington's Pharmaceutical Sciences, 1990). Some variation in dosage will necessarily occur depending on the condition of the subject. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject.

[0066] An effective amount of therapeutic or prophylactic composition is determined based on the intended goal. The term "unit dose" or "dosage" refers to physically discrete units suitable for use in a subject, each unit containing a predetermined quantity of the composition calculated to produce the desired responses discussed above in association with its administration, *i.e.*, the appropriate route and regimen. The quantity to be administered, both according to number of treatments and unit dose, depends on the protection desired.

[0067] Precise amounts of the composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the subject, route of administration, intended goal of treatment (alleviation of symptoms versus cure), and potency, stability, and toxicity of the particular composition.

[0068] Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically or prophylactically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above.

IV. EXAMPLES

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion. One skilled in the art will appreciate readily that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those objects, ends and advantages inherent herein. The present examples, along with the methods described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses which are encompassed within the spirit of the invention as defined by the scope of the claims will occur to those skilled in the art.

EXAMPLE 1

PEPTIDE FIBRILS AS IMMUNE ADJUVANTS

A. RESULTS

[0069] **Peptide Design and Supramolecular Assembly.** The peptide Q11 was previously designed as a self-assembling transglutaminase substrate (Collier and Messersmith, 2003) and was a variation on the DN1 peptide originally described by Aggeli and coworkers (Aggeli *et al.*, 1997; Riley *et al.*, 2009). A peptide containing a Q11 self-assembling domain was designed to include in tandem an OVA₃₂₃₋₃₃₉, a 17-amino acid peptide from chicken egg ovalbumin (FIG. 1). OVA₃₂₃₋₃₃₉ (ISQAVHAAHAEINEAGR (SEQ ID NO:26), hereafter referred to as OVA) is an H-2^b-restricted class II peptide containing multiple antigenic determinants, including known T and B cell epitopes (Yang and Mine, 2009). The self-assembling epitope peptide (O-Q11) was produced by solid phase synthesis and included a hydrophilic Ser-Gly-Ser-Gly spacer between the OVA and Q11 domains, with the OVA domain positioned at the N-terminus (FIG. 1B).

[0070] When dissolved in water at concentrations of 40 mM and lower, O-Q11 formed no visible precipitate. However, similar to Q11 and to other previously reported Q11 derivatives (Collier, 2008; Collier and Messersmith, 2003; Jung *et al.*, 2008), it formed networks of laterally entangled fibrils when it was first dissolved in water and then added to salt-containing buffers such as phosphate-buffered saline (PBS), (FIG. 1A, FIG. 2). By TEM, O-Q11 in PBS appeared as long, unbranched fibrils with widths of about 15 nm (FIG. 2C). Although the length of these fibrils was not directly measured, the relative scarcity of fibril ends in TEM images suggested that the fibril length was on the order of microns. Circular

dichroism of O-Q11 showed a single concentration-dependent minimum at 229-232 nm (FIG. 2E). This spectrum is consistent with a high degree of β -sheet or β -turn structure, and it is similar to the spectra of Q11 and mixtures of Q11 with other previously reported ligand-bearing Q11 derivatives (Jung *et al.*, 2009; Collier and Messersmith, 2003).

5 [0071] **Epitopes were functionally displayed on O-Q11 fibrils.** The availability of the OVA epitope on the surface of O-Q11 nanofibers was confirmed by TEM and by ELISA. To label epitopes in TEM samples, an N-terminally biotinylated O-Q11 was synthesized with a single biotin tag directly adjacent to the OVA sequence. This biotinylated peptide produced fibrils that appeared morphologically similar to O-Q11 (FIG. 2D). Five-nanometer
10 streptavidin-conjugated gold particles were then used to probe epitope availability on the fibril surface, with unmodified Q11 serving as a negative control. Biotin-O-Q11 fibrils stained strongly with streptavidin-gold, whereas Q11 samples bound negligible numbers of particles (FIG. 2B-2D), demonstrating that a significant portion of the peptides' N-termini were available on the surface of the fibrils. To confirm this finding and to quantify the availability
15 of the entire epitope, ELISA was employed. Plates coated with OVA and O-Q11 peptides were probed with antisera from mice immunized with OVA, either with or without complete Freund's adjuvant (CFA). Antisera from CFA-adjuvanted groups showed similar titers of OVA-reactive IgG, whether measured on OVA plates or on O-Q11 plates, and both showed low backgrounds for antisera from non-adjuvanted groups (FIG. 2F). This result indicated
20 that the OVA epitope was functionally presented on the surface of the Q11 fibrils, and that plates coated with O-Q11 fibrils produced similar signal strengths to plates coated with the non-fibrillized OVA peptide, allowing the sera of mice immunized with different peptides to be compared. Slightly higher titers were observed for the O-Q11-coated plates in both cases, but it was not statistically significant.

25 [0072] **High IgG titers were elicited by O-Q11 without adjuvant in mice.** To investigate how fibrillization affected the immunogenicity of OVA, C57BL/6 mice were immunized subcutaneously with the different peptides and boosted with additional peptide at 28 days (see methods). Serum was collected seven days after the boost, and levels of various immunoglobulins were measured. It was found that fibrillized Q11 alone did not raise any
30 detectable IgG, whether delivered with or without CFA (FIG 3A-3B). This result reiterated previous findings that Q11 was not immunogenic (Jung *et al.*, 2009) and further indicated that Q11 continued to be non-immunogenic even when delivered in CFA. Also, Q11 and

functionalized Q11 peptides did not induce cell death in cultures of primary human endothelial cells, indicating that the basic Q11 sequence was non-cytotoxic as well as non-immunogenic (Jung *et al.*, 2009; Jung *et al.*, 2008).

[0073] In surprising contrast to the immeasurably low immunogenicity of Q11, O-Q11 elicited high IgG titers without any added adjuvant (FIG. 3A). Even higher titers were produced when it was delivered in CFA (FIG. 3B). Anti-peptide IgG titers were similar between mice injected with O-Q11 in PBS and OVA peptide in CFA, indicating that the Q11 sequence itself functioned as a strong adjuvant. O-Q11 antisera also bound to OVA-coated plates, demonstrating that the epitope was conserved (FIG. 3C). O-Q11 antiserum reactivity to OVA-coated plates also excluded the possibility that the high antibody titers found in O-Q11 antisera were a measurement artifact arising from increased antigen density on fibril-coated ELISA plates. In addition, endotoxin levels were less than 0.3 EU/mL for all samples (Table 2), eliminating the possibility that inadvertent contamination caused the observed adjuvant effect. O-Q11 antisera also reacted with Q11, though at smaller, statistically insignificant levels (FIG. 3C), possibly indicating a small degree of epitope spreading to the Q11 domain.

TABLE 2

	Purity (%) by HPLC ^a	Endotoxin (EU/mL) ^{a,b}	(<i>m/z</i>) calc'd	(<i>m/z</i>) found ^a
Q11	92.0-97.5%	0.024-0.098	1526.7	1527.2-1529.4
OVA ₃₂₃₋₃₃₉	91.6-95%	bkgd-0.112	1773.9	1774.0-1774.3
O-Q11	96.2-98.0%	0.08-0.28	3528.8	3528.3-3530.1

^a Ranges represent high and low values among three batches for each peptide.

^b All are within acceptable limits [Malyala P, Singh M (2008), Endotoxin limits in formulations for preclinical research *J Pharm Sci* 97, 2041-2044].

[0074] It is contemplated that the multivalent surface display of the epitope on the fibrils was the source of Q11's strong adjuvant properties. Alternatively, if Q11 functioned as an adjuvant by activating Toll-like receptors, similarly to LPS or unmethylated CpG motifs, or if it simply slowed the diffusion of the epitope from the injection site by surrounding it with fibrils (the so-called "depot effect"), then outright conjugation of the epitope and the fibril would not be required. Additionally, if Q11 fibrils functioned in a manner similar to particulate adjuvants such as aluminum salts, whereby the adsorption and entrapment of the antigen onto and within the particle is sufficient for adjuvancy, then conjugation would also not be required. To investigate this aspect, mice were injected with unconjugated mixtures of

Q11 peptide and OVA peptide. Notably, the strong antibody response generated by O-Q11 was completely abolished in the absence of covalent coupling between the Q11 fibrillizing domain and the epitope domain (FIG. 3D). No detectable IgG was observed for mixtures of OVA and Q11. This result indicated that Q11's adjuvant properties were dependent on its covalent attachment to the epitope peptide.

[0075] To determine the nature of the immune response to Q11-adjuvanted peptides, the isotypes of the responding antibodies were evaluated. For both OVA in CFA and fibrillized O-Q11, the dominant antibody isotype was IgG1, with smaller amounts of IgG2a, IgG2b, IgG3, and IgM being produced for both (FIG. 4). Comparing CFA-adjuvanted responses with Q11-adjuvanted responses, IgG1, IgG2a, and IgG3 were produced in statistically similar quantities, but IgG2b production was greater in the CFA-adjuvanted group, and IgM production was greater in the Q11-adjuvanted group.

[0076] To investigate the involvement of T cell help in the immune responses to O-Q11, splenocytes from immunized mice were challenged *in vitro* with the peptides, and the production of interferon- γ (IFN- γ), interleukin-2 (IL-2), and interleukin-4 (IL-4) was measured. These three cytokines were selected to provide measures of either a Th1 response (IFN- γ and IL-2) or a Th2 response (IL-4). However, somewhat surprisingly, when splenocytes from immunized mice were challenged *in vitro* with the immunizing peptide, they did not produce significant levels of any of these three cytokines compared with positive controls (FIG. 5).

[0077] Attaching a short self-assembling amino acid sequence to a peptide epitope's C-terminus can dramatically enhance the peptide's immunogenicity. The results indicate that fibrillizing peptide domains may be useful as simple adjuvant systems for peptide-based immunotherapies, and these results also provide guidance for the development of non-immunogenic peptide biomaterials within applications such as regenerative medicine. As a means to specifically enhance peptide immunogenicity, the novel Q11-based approach reported here has a number of non-limiting advantages. For example, a self-assembling peptide domain can be easily added to any known epitope using conventional solid phase peptide synthesis. Also, by utilizing self-assembly, highly multivalent nanoscale objects can be directly produced from only one molecule, which enables precision in the production, purity, and study of the material. In contrast, many adjuvants currently employed or under development are comprised of multiple molecular constituents or heterogeneous mixtures,

making their definition, formulation, purification, and characterization challenging. For example, immunotherapies based on attenuated live viruses or heat-killed organisms contain intrinsic adjuvants such as lipopolysaccharide or unmethylated CpG motifs that are critical to their efficacy (McKee *et al.*, 2007). Adjuvants based on natural products such as saponins or squalene (Sun *et al.*, 2009) are by nature associated with some degree of molecular heterogeneity, and particulate adjuvants such as aluminum salts depend on antigen adsorption or entrapment, processes which are complexly dependent on multiple chemical and physical factors during formulation (Marrack *et al.*, 2009; McKee *et al.*, 2007). Accordingly, specific molecular features of current adjuvants are not easily adjusted independently within a given vaccine formulation, making it difficult both to optimize an immunotherapy as well as understand its mechanism of action. Such efforts will be greatly enhanced with the availability of chemically defined adjuvants.

B. MATERIALS AND METHODS

[0078] **Peptide Synthesis and Purification.** Peptides were synthesized using standard Fmoc chemistry as previously reported (Jung *et al.*, 2009; Jung *et al.*, 2008). For TEM studies, O-Q11 was N-terminally biotinylated on-resin using biotin *o*-nitrophenyl ester. Peptides were purified using a Varian ProStar HPLC system, Grace-Vydac C18 reverse phase columns, and water-acetonitrile gradients. Peptide identity and purity were confirmed by MALDI-MS and HPLC, respectively (Table 2). Endotoxin levels of all immunizations were < 0.3 EU/mL by LAL chromogenic endpoint assay (Lonza), well within acceptable limits (Table 2).

[0079] **Circular Dichroism.** An AVIV 202 CD spectrometer (Aviv Biomedical, NJ), 0.1 cm path length quartz cells, and initial disaggregation in TFA were employed as previously reported (Jung *et al.*, 2009). Working concentrations were prepared in degassed water using Phe absorbance at 257 nm. Owing to peptide fibrillization and the resultant low CD signal strength, spectra below 220 nm could not be measured accurately and so are not reported.

[0080] **Transmission Electron Microscopy.** Peptides were dissolved in deionized water and mixed 6:1 with PBS to produce working peptide concentrations of 330 μ M. After fibrillizing for 4h, peptides were applied to 400 mesh gold grids with carbon support films, negative-stained with 1% uranyl acetate, and imaged on a Tecnai F30 TEM. For gold staining, prior to negative-staining grids were placed upside-down on a droplet of blocking solution (0.2% acetylated BSA, 0.1% gelatin from cold water fish skin in PBS) for 5 min, then

for 2 h on a droplet of 5 nm colloidal gold conjugated to streptavidin (Sigma). Grids were washed once with blocking solution, twice with PBS, and stained with 1% uranyl acetate.

[0081] **Immunizations.** Peptides were dissolved in sterile water (8 mM) and allowed to fibrillize overnight at 4°C. Stock solutions were then diluted in sterile, endotoxin-free PBS to working concentrations. Female C57BL/6 mice (6-8 weeks old, Taconic Farms, IN) were each given two 50 µL subcutaneous injections near the shoulder blades, each injection containing 100 nmol of peptide. CFA-adjuvanted groups received the same volume and total peptide dose, prepared by emulsifying peptide/PBS solutions 1:1 in CFA. Mice were boosted at 28 days with two additional 25 µL injections, each containing 50 nmol of peptide. CFA groups were boosted in incomplete Freund's adjuvant (IFA). Mice receiving mixtures of Q11 and OVA received 100 nmol of each peptide in the first injection and 50 nmol of each in the second. Seven days after the boost, the mice were sacrificed, and sera and spleens were harvested. In all animal work, institutional guidelines for the care and use of laboratory animals were strictly followed under a protocol approved by the University of Chicago's Institutional Animal Care and Use Committee.

[0082] **Determination of antibody titers.** High-binding ELISA plates (eBioscience) were coated with either 20 µg/mL peptide in PBS or PBS alone (for uncoated background subtraction) overnight at 4°C. Wells were blocked with 1% BSA/0.5% Tween 20 in PBS, and serial dilutions of serum between 1:10² and 1:10⁹ were applied, followed by peroxidase-conjugated goat anti-mouse IgG (H+L) (Jackson Immuno Research). Washing steps were performed with 0.5% Tween 20 in PBS, plates were developed using TMB substrate (eBioscience), and absorbance values were read at 450 nm. To determine titers for each antiserum, background absorbance values from uncoated wells were subtracted from coated wells, and net absorbances were compared to cutoff values. The cutoff consisted of the mean plus three times the standard deviation of the negative control group (mice receiving OVA without adjuvant) for each corresponding dilution. Any sample dilutions having absorbances above this cutoff value were considered positive readings. The titer was considered as the highest dilution for which it and all lower dilutions had positive readings. If no positive dilutions were present the titer was considered to be 10². Negative control mice (OVA without adjuvant) did not raise detectable IgG, and no single mouse in the negative control groups had absorbance values greater than three standard deviations above the group's mean for a given dilution; therefore all negative control mice are reported as having titers of 10²,

which is the baseline level of detection for this study. Antibody isotypes were analyzed similarly using a mouse monoclonal antibody kit containing goat anti-mouse IgG1, IgG2a, IgG2b, IgG3, and IgM (Sigma).

[0083] **Splenocyte isolation and challenge.** Spleens of the immunized mice were pressed
5 through 70 μ m cell strainers, and isolated splenocytes were washed in RPMI medium containing 10% FBS. Red blood cells were lysed using ACK buffer (150 mM NH_4Cl , 10 mM KHCO_3 /0.1 mM EDTA) and washed twice. 1×10^6 cells/well (96 well plate) were plated in complete T cell medium (S-MEM supplemented with 3.75 mM dextrose, 0.9% L-glutamine, 0.6% essential amino acids, 1.26% non-essential amino acids, 0.9% sodium pyruvate, 9 mM
10 sodium bicarbonate, 95 μ M gentamycin, 140 μ M penicillin-G, 60 μ M streptomycin sulfate, 44 μ M 2-mercaptoethanol, and 10% fetal bovine serum) containing 5 μ g/ml challenging peptide or no peptide. After a 24 h, interferon- γ (IFN- γ), IL-2, and IL-4 concentrations were measured in the culture medium using a sandwich ELISA. Antibodies and reagents were purchased from eBioscience, and cytokine concentrations were calculated from standard
15 curves.

[0084] **Statistical Analysis.** Statistical analysis was performed by ANOVA with Tukey's HSD post hoc comparisons. The data reported in FIGs. 3A and FIG. 4 represent three separate experiments, each containing five mice per group. Positive and negative controls were not statistically different between the three trials, and so the data were pooled into the
20 groups of 15 shown.

EXAMPLE 2

CHARACTERIZATION OF IMMUNE RESPONSES TO Q11 LINKED PEPTIDES

A. Results

[0085] *Antibody responses to self-assembled peptide antigens are long-lived.* In a previous
25 study it was shown that conjugating an antigenic peptide (OVA) to the self-assembling peptide domain Q11 results in robust antibody responses against OVA. It was found that mice immunized with 100 nmol of the fibrillized antigen elicited similar antibody titers as the free peptide administered in complete Freund's adjuvant (CFA). The dose dependence and longevity of the antibody response to OVA-Q11 was further investigated and antibody
30 responses against the malarial peptide epitope (NANP)₃ coupled to Q11 were also characterized. Mice were immunized with two different doses of OVA-Q11 (100 nmol and

50 nmol), or 100 nmol of (NANP)₃-Q11 and boosted with half the dose at wk 4. Mice were bled on a weekly basis up to wk 6, once at wk 8, and once every four weeks thereafter.

[0086] Serum ELISAs indicated that antibody production was long-lived, as antibodies were detectable for at least 36 wks in OVA-Q11-immunized mice. Similar levels were detected in OVA peptide delivered in CFA. The antibody levels spiked approximately 2.5 fold after the boost at wk 4 and reached maximum levels around wk 6 in the OVA-Q11 immunized mice for both the 100 nmol and 50 nmol groups. Although the antibody production at earlier time points (wk 3 and wk 4) was higher in the 100 nmol group, no significant difference was observed after the boost and throughout the duration of the study. This suggested that immunizing mice with 50 nmol of OVA-Q11 elicited antibody responses with similar magnitude and longevity as mice immunized with 100 nmol of OVA-Q11.

[0087] Mice immunized with (NANP)₃-Q11 also elicited sustained antibody responses that were detectable for up to 28 wks; however, unlike OVA-Q11 no spike in antibody levels was observed after the boost. These results demonstrate that self-assembled peptides decorated with peptide antigens can elicit long term antibody production in mice without the need for frequent boosting.

[0088] *Co-assembled peptide antigens elicit immune responses independently.* Transmission electron microscopy showed that OVA-Q11, (NANP)₃-Q11, and co-assembled OVA-Q11/(NANP)₃-Q11 self-assembled into fibers in phosphate buffered saline. To investigate if antibodies were raised simultaneously against multiple self-assembled antigens co-administered in vivo, mice were immunized with OVA-Q11 and (NANP)₃-Q11 either separately or as co-assembled fibrils. The total peptide concentration was the same in both groups. Injecting the peptides either separately or as co-assembled fibrils, resulted in production of antibodies against both epitopes. Antibodies were produced for up to 16 wks with similar magnitudes, suggesting that the presence of one peptide did not alter immune responses towards the other. Interestingly, the spike in the antibody levels of OVA-Q11 at wk 5 was not observed. However, there was a small increase in the antibody levels in NANP-Q11 boosted mice at wk 5 in both groups, which was not detected when mice were immunized with (NANP)₃-Q11 alone.

[0089] *Antibodies generated against self-assembled peptides cross-reacted with whole proteins.* For efficient protection against disease antibodies raised against single epitopes

must react with and neutralize whole proteins or pathogens. To determine if the antibodies produced against self-assembled OVA peptide reacted with whole ovalbumin, serum derived from OVA-Q11 immunized mice was applied to ELISA plates coated with OVA-Q11 or ovalbumin. Antibodies raised against OVA-Q11 were reactive against ovalbumin.

5 [0090] ***Peptide Assemblies were observed in the lymph nodes for extended time periods.*** Immunohistochemistry data and staining for biotin on the peptides indicated that OVA-Q11 was localized to the draining lymph nodes over time. Peptide assemblies (stained brown and indicated by arrows) were found at the cortex of the lymph nodes by wk 1 and continued to persist up to wk 6. No peptide was observed at time points earlier than one week (1 day and 3
10 days). Although the mechanism of trafficking is unknown, co-staining for macrophages, dendritic cells, or B cells might provide further insights into the uptake and processing of these peptides *in vivo*.

[0091] ***Antibody responses to self-assembled peptides are T cell-dependent.*** The robust antibody responses and isotype class switching observed with OVA-Q11 suggested
15 involvement of CD4⁺ T cells. To determine the requirement for T cells, an adoptive T cell transfer assay was performed. Specifically, mice were injected with CFSE labeled OTII cells, which express receptors for the H-2^b restricted OVA epitope. Antigen-mediated proliferation causes a decrease in the CFSE intensity which can be detected by flow cytometry.

[0092] Robust proliferation of OTII cells in the OVA-Q11 and OVA-CFA immunized mice
20 was observed by the shift in the CFSE intensity peak which demonstrated that T cells were involved in the immune responses against OVA-Q11. Quantifying the shift in the CFSE intensity indicated that more than 95 % of the transferred cells in both OVA-Q11 and OVA-CFA immunized mice proliferated. In contrast, a negligible shift in CFSE intensity was observed for Q11-immunized mice. The extent of proliferation was found to be similar in
25 both the spleen and the lymph nodes. Immunization with OVA-Q11 after adoptive transfer of OTII cells elicited rapid antibody production compared to mice that were not given OTII cells. Interestingly, mice that were injected with OTII cells and immunized OVA-CFA failed to generate antibody responses within the same time frame.

[0093] To confirm the necessity of T cells, KO mice lacking both the $\alpha\beta$ and $\gamma\delta$ receptors
30 for CD4⁺ T cells were immunized with OVA-Q11 along with wild type controls. No antibody production was observed in mice lacking the T cell receptors over 6 wks suggesting that T

cells are required for antibody production against OVA-Q11. The wild type control mice responded as expected. Together, these data support the earlier T cell requirement conclusion. To ensure that the KO mice are capable of eliciting immune responses, they were immunized with a T-independent antigen, NP-Ficoll. Antibody production against NP-Ficoll was observed in the KO mice demonstrating their capability to mount B cell-mediated immune responses and reconfirming that antibody responses against OVA-Q11 were T cell-mediated. This finding might not be surprising because OVA is a strong MHC class II peptide, containing both B and T cell determinants. To further determine if T cells are required for other epitopes, T cell receptor KO mice were immunized with (NANP)₃-Q11 which resulted in no antibody production. These findings suggest that CD4⁺ T cells might play an important role in the immune responses against self-assembled antigens.

B. Materials and Methods

[0094] **Peptide Synthesis and Purification** Peptides were synthesized on a CSBio136-XT peptide synthesizer using standard Fmoc chemistry, cleaved using cocktail solution (95 % trifluoroacetic acid, 2.5 % water and 2.5 % triisopropyl silane), precipitated in diethyl ether, and lyophilized. Peptides were purified using a Varian ProStar HPLC system, Grace-Vydac C18 reverse phase columns, and water/acetonitrile gradients. The acetonitrile was removed by centrifugal evaporation and the peptides were lyophilized and stored at -20 °C until further use. Peptide identity and purity were confirmed by MALDI-MS and HPLC, respectively. Endotoxin levels of all formulations were tested using a Limulus Amebocyte Lystae (LAL) chromogenic end point assay (Lonza, USA). Endotoxin levels in all immunization formulations were found to be less than < 0.22 EU/mL. The peptides synthesized were NANPNANPNANPSGSGQQKFQFQFEQQ ((NANP)₃-Q11 (SEQ ID NO:27)), and ISQAVHAAHAEINEAGRSGSGQQKFQFQFEQQ (OVA-Q11 (SEQ ID NO:28)).

[0095] **Transmission Electron Microscopy** Stock solutions of 1 mM peptides were allowed to fibrillize in PBS for 4 h at room temperature or overnight at 4 °C, diluted to 0.25 mM, and pipetted onto carbon-coated 200 mesh lacey grids (Electron Microscopy Sciences). For the co-assembled fibrils, OVA-Q11 and (NANP)₃-Q11 peptides were mixed as dry powders, dissolved in deionized water, and diluted in PBS to produce working peptide concentration of 0.5 mM. After fibrillizing for 4 h, peptides were applied to the grids. The grids were stained with 1% uranyl acetate for 2 minutes, and imaged with a FEI Tecnai F30 transmission electron microscope.

[0096] ***Animals and Immunizations*** Peptides were dissolved in sterile water (8 mM stock), incubated overnight at 4 °C, and diluted in sterile PBS (2 mM working concentration) prior to immunizations. For the malaria peptide, (NANP)₃-Q11, the formulations were incubated in PBS overnight to ensure complete fibril formation. To prepare co-assembled fibers of OVA-Q11/(NANP)₃-Q11 or OVA-Q11/Biotin-Q11, the peptides were combined as dry powders, mixed thoroughly, and dissolved in sterile water. The peptides were allowed to co-assemble overnight at 4 °C and fibrillized in sterile PBS. Female C57BL/6 mice (6-8 weeks old, Taconic Farms, IN) were immunized subcutaneously with two 50 µL injections in the back, with each injection containing 100 nmol of peptide. Mice were boosted at 28 days with two additional 25 µL injections, each containing 50 nmol of peptide. Blood was drawn on a weekly basis via the submandibular maxillary vein, the serum extracted, and stored at -80 °C until use. To identify local tissue responses and peptide distribution, mice were injected intramuscularly with 50 µL of peptide solution (90 % OVA-Q11 +10 % Biotin-Q11) in each thigh and the muscles and inguinal lymph nodes were extracted at predetermined time points. In all animal work, institutional guidelines for the care and use of laboratory animals were strictly followed under a protocol approved by the University of Chicago's Institutional Animal Care and Use Committee.

[0097] ***Determination of Antibody Production*** ELISA plates (eBioscience) were coated with 20 µg/mL of peptide or 0.5 µg/mL of whole protein in PBS overnight at 4 °C. The plates were blocked with 200 µL of 1% BSA in PBST (0.5% Tween-20 in PBS) for 1 h and serial dilutions of serum between 1:10² and 1:10⁹ were applied (100 µL/well) for 1 h at room temperature. Peroxidase-conjugated goat anti-mouse IgG (H+L) (Jackson Immuno Research) (1:5000 in 1 % BSA-PBST, 100 µL/well) was then applied for 30 min and the plates were developed using TMB substrate (100 µL/well, eBioscience). The reaction was stopped using 50 µL of 1 M phosphoric acid and 100 µL of the solution was transferred to fresh plates and absorbance values were read at 450 nm. Absorbance values of PBS (no antigen) coated wells were subtracted to account for background. The plates were washed between each step with PBST.

[0098] ***Immunohistochemistry*** Freshly dissected skeletal muscle and inguinal lymph nodes were fixed overnight with 4% formaldehyde in phosphate-buffered saline (pH 7.2) and the tissue was processed and embedded in paraffin at the Human Tissue Resource Center (University of Chicago). The paraffin blocks were cut on a microtome (Leica, USA) into 4

µm thick sections and were deparaffinized with xylene and rehydrated with gradient ethanol. The sections were boiled in 10 mM sodium citrate solution (pH 6.0) for 10 min to retrieve the antigens and blocked with 5% BSA in PBS for 1hr. The sections were then incubated with Horseradish Peroxidase Avidin D (Vector Laboratories, CA) for 3hrs, and the biotin was visualized using a peroxidase substrate diaminobenzidine kit (Vector Laboratories, CA). The sections were also counterstained with Mayer's hematoxylin solution (Sigma-Aldrich, USA) for 10mins. The slides were dehydrated with gradient ethanol and xylene and mounted with Permount Mounting Medium (Fisher Scientific, PA). Images were acquired using a Zeiss Axioskop at the Microscopy Core Facility (University of Chicago).

[0099] ***Adoptive Transfer of T cells*** OTII transgenic mice on C57BL/6 background, whose T cells recognize the OVA peptide and carry a marker to distinguish them from naïve T cells from B6 mice (CD90.1 congenic). In vivo CD4⁺ T cell proliferation was analyzed after adoptive transfer into mice and immunization with the peptides. Briefly, splenocytes and lymph nodes of OTII⁺ C57BL/6 mice were processed into a single cell suspension and enriched for CD4⁺ T cells, by negative magnetic separation (Miltenyi Biotec). The cells were then labeled with 10 µM carboxyfluorescein succinimidyl ester (CFSE) and adoptively transferred into mice (5x10⁵ OTII cells/mouse, retroorbital injection) 24 h before peptide immunizations. The next day, mice were immunized with 100 nmol of OVA-Q11 in PBS, OVA in CFA, or Q11 in PBS at two different sites subcutaneously. Five days after immunizations, spleens and lymph nodes were harvested, processed into single cell suspensions, and stained for flow cytometry in 1%BSA in PBS containing 0.02% sodium azide (FACS buffer) for 1 hour at 4 °C with APC-labeled anti-CD4 (RM 4-5) (BD Biosciences, NJ) and PECy7-labeled anti-CD90.1 (HIS51) (eBioscience, CA) respectively. Anti-CD16/32 (2.4G2.1) (University of Chicago Immunology Core) was used to prevent nonspecific antibody binding. After staining, cells were washed twice with FACS buffer and samples were run on the LSR-II (BD Biosciences, NJ) flow cytometer and analyzed for evidence of proliferation as indicated by dilution of CFSE intensity using. FlowJo cytometry analysis software (Tree Star, OR) was used to analyze and quantify the results. Blood was collected through cardiac exsanguinations and serum was extracted and stored at -80 °C until further use.

EXAMPLE 3

MODIFICATION OF FIBRIL MONOMERS

A. Results.

[00100] **Synthesis of Phosphonate-Q11.** MALDI-TOF-MS analysis demonstrated that phosphonate-Q11 can be synthesized in good yield by reacting phosphonate-maleimide with cys-terminated Q11. Similar to Q11, phosphonate-Q11 self-assembled into fibrils when dissolved in 1x PBS at a concentration of 0.25 mM.

[00101] **Cutinase-GFP reacts efficiently with mixed Q11:phosphonate-Q11 fibrils.** The reaction of cutinase with phosphonate results in the release of p-nitrophenol, which absorbs light at 403 nm. The absorbance of solutions containing 1 mM Q11:phosphonate-Q11 (99:1 molar ratio) and 4.5, 9, or 15 μ M cutinase-GFP at 403 nm increased as a function of time. Absorbance values reached a plateau for the 4.5 μ M cutinase-GFP condition by 300 minutes, which suggested that the reaction approached completion over this time frame. For the 9 and 15 μ M cutinase-GFP conditions, a time course of nearly 600 minutes was required for these reactions to approach completion.

[00102] To characterize the extent of reaction between cutinase-GFP and phosphonate-Q11, unreacted cutinase-GFP was removed from the peptide fibrils by serial centrifugation washes and then measured the fluorescence intensity of the purified fibrils. When 0.9 μ M or 1.8 μ M cutinase-GFP was reacted with 1 mM Q11:phosphonate-Q11 (99:1 molar ratio), the fluorescence intensity of fibrils was similar to the fluorescence of cutinase-GFP in 1x PBS at the same concentration, suggesting that the reaction proceeds nearly quantitatively under these conditions. When the cutinase-GFP concentration was increased to 4.5, 9 or 15 μ M, however, the resulting fibril fluorescence intensity was equal to GFP concentrations of 2.5, 4.12 or 4.75 μ M, respectively, which corresponds to an extent of reaction of approximately 50% for each condition. This suggests that as stoichiometric ratios of cutinase and phosphonate are reached, the extent of reaction is limited by phosphonate moiety availability, which may be influenced by packing of protein onto the fibrils (i.e. a steric limit) or burying of phosphonate moieties within the fibrils during assembly.

[00103] The influence of fibril preparation on the reaction between phosphonate-Q11 and cutinase-GFP was also characterized. The reaction kinetics and extent of reaction between cutinase-GFP and phosphonate-Q11 were similar for two different cutinase-GFP

concentrations, regardless of whether the fibrils were prepared by mixing an aqueous solution of Q11 with an aqueous solution of phosphonate-Q11 at a 99:1 volume ratio or by dissolving a mixture consisting of a 99:1 molar ratio of dry Q11 and phosphonate-Q11, illustrating robustness in formulating the materials.

5 [00104] **Mice immunized with GFP-Q11 fibrils produced antibodies against cutinase-GFP.** CB57BL/6 mice immunized with 3.58 μ M GFP-cutinase conjugated to 1 mM Q11:phosphonate-Q11 fibrils (99:1 molar ratio) produced IgG antibodies that were reactive against microtiter plates coated with GFP-cutinase-phosphonate-Q11 fibrils by 1 week post-immunization. The amount of total IgG produced by these mice increased by week 2, and
10 then decreased at week 3 and 4. Compared to mice injected with GFP-cutinase emulsified in complete Freund's adjuvant, a commonly used potent adjuvant in mouse models, the total amount of IgG antibodies produced by mice immunized with GFP-cutinase conjugated to mixed Q11:phosphonate-Q11 fibrils were lower, however, the trajectory of antibody production was similar in both groups. Importantly, mice immunized with GFP-cutinase in 1x
15 PBS demonstrated low levels of antibody production through 4 weeks, indicating that the observed antibody production in mice immunized with GFP-cutinase conjugated to mixed Q11:phosphonate-Q11 fibrils is not due to the injection of foreign proteins into the mice, but rather requires the action of an adjuvant.

[00105] Mice were boosted with a half dose of GFP-cutinase conjugated to
20 Q11:phosphonate-Q11 fibrils (99:1 molar ratio) at day 31, which resulted in increased IgG antibody levels that were maintained through week 6. The total IgG produced post-boost was similar in mice immunized and boosted with GFP-cutinase conjugated to mixed Q11:phosphonate-Q11 fibrils or mice immunized with GFP emulsified in CFA and boosted with GFP-cutinase emulsified in incomplete Freund's adjuvant. This suggested that
25 chemically-defined self-assembled fibrils decorated with protein antigens are as effective as ill-defined oil emulsions as adjuvants for prime-boost vaccination strategies.

[00106] To determine the reactivity of antibodies produced by mice immunized with GFP-cutinase conjugated to mixed Q11:phosphonate-Q11 fibrils serum collected at week 5 was reacted with ELISA plates coated with GFP-cutinase-phosphonate-Q11 fibrils or GFP-
30 cutinase. Antibody reactivity against toward both plates was similar, which indicates that the antibodies produced around week 5 are primarily reactive towards the GFP-cutinase fusion protein and are relatively unreactive towards the mixed Q11:phosphonate-Q11 adjuvant.

[00107] Antibody isotype is an important indicator of the immunological pathways involved in antibody production. IgG1 was the prominent isotype in serum collected at week 5 from mice immunized with GFP-cutinase conjugated to mixed Q11:phosphonate-Q11 fibrils, while lower levels of IgG2a, IgG2b, IgG3, or IgM were also present. Interestingly, while IgG1 was also the major antibody isotype present in serum collected from mice immunized with GFP-cutinase emulsified in CFA at week 5, IgG2b was also elevated compared to other isotypes. The predominance of IgG1 suggests that for both adjuvants, antibody production involves Th-2 mediated, IL-4-dependent, B cell isotype switching.

B. Materials and Methods

[00108] **Cutinase-GFP expression.** Origami B (DE3) *E. coli* transformed with the cutinase-GFP fusion vector were cultured in 10 mL 2XTY media with 100 µg/mL carbenicillin and 50 µg/mL kanamycin A overnight at 37°C on a rotary shaker at 2200 rpm. After overnight culture, *E. coli* were subcultured into a 1 L flask containing 2XTY media with 100 µg/mL carbinocillin and 50 µg/mL kanamycin A. The flask was incubated at 37°C in a rotary shaker at 2200 rpm and the cells were allowed to proliferate until reaching an optical density at 600 nm of 0.6-0.8. When the *E. coli* reached an appropriate density, expression of cutinase-GFP was induced by adding 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) to the medium. IPTG-induced cells were cultured for 16 hours at 18° C on a rotary shaker at 2200 rpm. At the end of the expression period, cells were pelleted by centrifugation at 9800 rpm for 10 minutes. Media was decanted from the pellet and *E. coli* was washed once by resuspending in 400 mL of buffer containing 50 mM Tris-HCl, 3 mM MgCl₂, 250 mM NaCl (Buffer A) followed by centrifugation at 9800 rpm for 10 minutes. Following centrifugation, buffer A was decanted from the pellet, *E. coli* was resuspended in 35 mL buffer A, and *E. coli* was transferred to a 50 mL conical tube. *E. coli* were lysed to release cutinase-GFP by adding 3.5 mL 10X BugBuster, 300 units DNase, and one eComplete mini EDTA-free protease tablet to the buffer and incubating for 20 minutes at room temperature on a table-top shaker. Cell debris was separated from GFP-cutinase by centrifuging the lysis buffer at 20000 rpm, 4°C for 35 minutes. His₆-tagged cutinase-GFP was further purified by column chromatography by passing the centrifugation supernatant over a cobalt column. The column eluent was collected and passed over the column a second time to increase yield of GFP-cutinase recovered. Protein bound to the cobalt column was washed with 10 column volumes of buffer A. Protein was eluted from the column by passing 50 column volumes of Buffer A

containing 0.5% Triton X-100 over the protein-bound column. The eluted protein was dialyzed overnight at 4°C against buffer containing 25 mM Tris-HCl, 150 mM NaCl, 0.05% NaN₃, pH 7.8 to exchange salts and remove endotoxin bound to Triton X-100. Protein was concentrated by centrifugation using an Amicon Ultra centrifugal filter. Protein molecular weight was analyzed by SDS-PAGE. GFP activity was characterized by exposing the protein to a 395 nm UV light and cutinase activity was characterized by incubating protein in 1x phosphate-buffered saline (pH 7.4) containing dinitrophenol and measuring absorbance at 405 nm. Protein was stored in buffer at 4°C or -20°C until use.

[00109] **Endotoxin quantification and removal.** Endotoxin level in GFP-cutinase was quantified using a Limulus ameobocyte lysate assay according to manufacturer's instructions. Endotoxin was removed from GFP-cutinase by: (1) adding cold Triton X-114 at a 1:10 (v/v) ratio to a solution of GFP-cutinase, (2) incubating this solution on ice for 10 minutes, (3) incubating this solution at 37°C for 20 minutes to precipitate endotoxin-loaded Triton X-114 micelles, (4) centrifuging at 4000 rpm for 5 minutes, and (5) collecting the endotoxin-free supernatant containing GFP-cutinase. This process was repeated once to ensure removal of endotoxin.

[00110] **Phosphonate-Q11 synthesis** - The peptides Q11 or C-SGSG-Q11 were synthesized on a CSBio 136-XT using a standard solid phase peptide synthesis protocol based on Fmoc-protected α -amine and HOBt, HBTU, DIEA activation. Peptide was cleaved from the resin by incubating in a cocktail containing 95% trifluoroacetic acid, 2.5% triisopropylsilane, and 2.5% water for 90 minutes. At the end of the cleavage reaction, the cocktail was passed through a filter to separate the peptide from the synthesis resin. The cocktail was then removed using a rotary evaporator and cold diethyl ether was added to precipitate the peptide. The peptide precipitate was collected by centrifuging at 3500 rpm for 5 minutes, the supernatant was decanted off, and the peptide was washed with cold ether. This process was repeated 5x. After the final centrifugation step, the peptide was dried over vacuum for 60 minutes, dissolved in 25 mL deionized water, frozen, and lyophilized to dryness. The dry peptide was analyzed by MALDI-TOF-MS. Peptide was purified to greater than 95% purity using an acetonitrile/water gradient on a Varian ProStar HPLC system equipped with a Grace-Vydac C18 reverse phase column. For phosphonate-Q11 synthesis, C-SGSG-Q11 was first dissolved in DI H₂O. DMSO containing maleimido-EG6-ethyl-p-nitrophenyl phosphonate was then added to the aqueous C-SGSG-Q11 solution and the reaction was allowed to proceed

at 37°C for 2 hours. At the end of the reaction, the solution was loaded directly onto a reverse-phase semi-prep scale C18 column and purified with a linear gradient of 75% can in DI H₂O + 0.1% Trifluoroacetic acid over 1 hour. Fractions were lyophilized to dryness and analyzed with MALDI-TOF-MS.

- 5 [00111] **Transmission Electron Microscopy** - A 1 mM peptide solution was allowed to fibrillize in PBS for 4 h at room temperature or overnight at 4 °C, at which point it was diluted to 0.25 mM and pipetted onto carbon-coated 200 mesh lacey grids (Electron Microscopy Sciences). The grids were stained with 1% uranyl acetate for 2 minutes, and imaged with a FEI Tecnai F30 transmission electron microscope.
- 10 [00112] **Reacting phosphonate-Q11 fibrils with cutinase-GFP** – Dry Q11 and phosphonate-Q11 were dissolved in deionized water at a 99:1 molar ratio to achieve a final concentration of 10 mM. 1x phosphate-buffered saline was added to the aqueous peptide solution to achieve a final concentration of 1.1 mM. A buffered solution containing 150, 90, 45, 18, or 9 µM GFP-cutinase was added to the buffered peptide solution to achieve a final
- 15 peptide concentration of 1 mM and a final protein concentration of 15, 9, 4.5, 1.8, or 0.9 µM. The reaction between cutinase-GFP and phosphonate-Q11 was allowed to proceed at room temperature for at least 10 hours. The extent of reaction between phosphonate-Q11 and cutinase-GFP was monitored by measuring the absorbance of the solution at 403 nm at specified time intervals. At the reaction end-point, unreacted cutinase-GFP was removed
- 20 from the cutinase-GFP-modified fibrils by centrifuging the reaction solution at 13000 rpm for 5 min, removing 70% of the supernatant with a pipet, replacing the removed volume of supernatant with fresh 1x PBS, and resuspending the fibril pellet by pipetting. This process was repeated 5 times to ensure removal of unreacted protein. After removing unreacted cutinase-GFP, the concentration of cutinase-GFP conjugated to phosphonate-Q11 fibrils was
- 25 quantified by measuring fluorescence intensity using a 395/509 (excitation/emission) filter set and comparing the fluorescence intensity readings to those collected from a standard curve of GFP fluorescence.

- [00113] **Immunization protocols** - 1 mM Q11:phosphonate-Q11 (99:1 molar ratio) and 4.5 µM cutinase-GFP were mixed under sterile conditions and allowed to react overnight at room
- 30 temperature. Unreacted cutinase-GFP was removed from the fibrils and the concentration of cutinase-GFP conjugated to fibrils was determined using the methods outlined above. For this particular study, the concentration of cutinase-GFP conjugated to fibrils was determined to be

3.58 μm . At day 0, C57BL/6 mice ($n = 5$) were immunized by subcutaneously injecting 50 μL of the cutinase-GFP conjugated fibril solution into each of two flanks (100 μL total injection volume). At this same time point, separate groups of C57BL/6 mice ($n = 5$) were also immunized by subcutaneously injecting 50 μL of solution containing 7.16 μm cutinase-GFP emulsified with complete Freund's adjuvant at a 50/50 (v/v) ratio (positive control) or 3.58 μm cutinase-GFP in 1x PBS (negative control) into each of two flanks (100 μL total injection volume). At day 31, mice were boosted by subcutaneously injecting 25 μL of the cutinase-GFP conjugated fibril solution, 7.16 μm cutinase-GFP emulsified with incomplete Freund's adjuvant at a 50/50 (v/v) ratio (positive control) or 3.58 μm cutinase-GFP in 1x PBS (negative control) into each of two flanks (50 μL total injection volume). Blood was drawn from each mouse weekly, serum was separated from the blood by centrifugation, and total serum IgG was quantified by ELISA. For ELISAs, microtiter plates were coated overnight at 4°C with 100 μL of either cutinase-GFP-phosphonate-Q11 fibrils or cutinase-GFP. Control wells were incubated with 100 μL of 1x PBS. After overnight coating, plates were washed 3x with 1x PBS containing 0.05% (v/v) Tween-20 (PBST). Plates were blocked with 0.1% bovine serum albumin in PBST (BSA-PBST) for 2 hours at room temperature. Serum was serially diluted 1:100 to 1:100000000 in BSA-PBST and 100 μL of each serum dilution was added to antigen-coated wells or control wells immediately after BSA blocking. Serum antibodies were allowed to bind to the plates for 60 minutes at room temperature, at which point plates were washed 5x with PBST. 100 μL of horseradish peroxidase-conjugated goat anti-mouse IgG (1:5000 dilution) in BSA-PBST was added to the wells. After a 45 minute incubation at room temperature, wells were washed 5x with PBST. 100 μL 1x TMB substrate was then added to the wells and allowed to react for 5 minutes at room temperature. At the reaction-endpoint, the reaction was quenched by adding 50 μL 1 M H_3PO_4 to the wells. 100 μL of each solution was then transferred to a new well of a microtiter plate and the absorbance of each solution at 450 nm was measured using a plate reader. Absorbance from control wells was subtracted from absorbance from antigen coated wells and these resulting values, as well as their associated mean, were plotted for each time point.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

5

U.S. Patent 4,578,770

U.S. Patent 4,596,792

U.S. Patent 4,599,230

U.S. Patent 4,599,231

10

U.S. Patent 4,601,903

U.S. Patent 4,608,251

U.S. Patent 6,651,655

U.S. Patent 6,733,754

U.S. Patent 6,793,923

15

Aggeli *et al.*, *Nature*, 386:259-262, 1997.Bettahi *et al.*, *Cancer Immunol. Immunother.*, 58:187-200, 2009.Cao *et al.*, *Neurosci.*, 9:25, 2008.Collier and Messersmith, *Bioconjug. Chem.*, 14:748-755, 2003.

20

Collier, *Soft Matter*, 4:2310-2315, 2008.Daftarian *et al.*, *Vaccine*, 24:5235-5244, 2006.Davis *et al.*, *Circulation*, 111:442-450, 2005.Dubois *et al.*, *J. Biomed. Mater. Res. B Appl. Biomater.*, 87:222-228, 2008.Genove *et al.*, *Biomaterials*, 26:3341-3351, 2005.

25

Gras *et al.*, *Biomaterials*, 29:1553-1562, 2008.Guler *et al.*, *Biomacromolecules*, 7:1855-1863, 2006.Hartgerink *et al.*, *Science*, 294:1684-1688, 2001.Holmes *et al.*, *Proc. Natl. Acad. Sci. USA*, 97:6728-6733, 2000.Horii *et al.*, *PLoS ONE*:2:e190, 2007.

30

Hsieh *et al.*, *J. Clin. Invest.*, 116:237-248, 2006.Ishii and Akira, *J. Clin. Immunol.*, 27:363-371, 2007.Jung *et al.*, *Biomaterials*, 29:2143-2151, 2008.Jung *et al.*, *Biomaterials*, 30:2400-2410, 2009.

- Lambrecht *et al.*, *Curr. Opin. Immunol.*, 21:23-29, 2009.
- Lutolf and Hubbell, *Nat. Biotechnol.*, 23:47-55, 2005.
- Maraskovsky *et al.*, *Immunol. Cell Biol.*, 87:371-376, 2009.
- Marrack *et al.*, *Nat. Rev. Immunol.*, 9:287-293, 2009.
- 5 McKee *et al.*, *Immunity*, 27:687-690, 2007.
- McSorley *et al.*, *J. Immunol.*, 169:3914-3919, 2002.
- Place *et al.*, *Nat. Mater.*, 8:457-470, 2009.
- Purcell *et al.*, *Nat. Rev. Drug Discov.*, 6:404-414, 2007.
- Remington's Pharmaceutical Sciences, 15th Ed., 1035-1038 and 1570-1580, 1990.
- 10 Riley *et al.*, *Biotechnol. Bioeng.*, 103:241-251, 2009.
- Schneider *et al.*, *J. Am. Chem. Soc.*, 124:15030-15037, 2002.
- Silva *et al.*, *Science*, 303:1352-1355, 2004.
- Sun *et al.*, *Vaccine*, 27:1787-1796, 2009.
- Toth *et al.*, *Int. J. Pept. Res. Ther.*, 14:333-340, 2008.
- 15 Tysseling-Mattiace *et al.*, *J. Neurosci.*, 28:3814-3823, 2008.
- Wendorf *et al.*, *J. Pharm. Sci.*, 95:2738-2750, 2006.
- Yang and Mine, *Biochem. Biophys. Res. Commun.*, 378:203-208, 2009.
- Zhou *et al.*, *Biomaterials*, 30:2523-2530, 2009.

WHAT IS CLAIMED IS:

1. An immunogenic composition comprising a peptide fibril coupled to a plurality of antigens.

2. The composition of claim 1, wherein the peptide fibril comprises a plurality of self-assembling peptides.

3. The composition of claim 2, wherein peptide fibril has a length of at least 0.5 to 100 μm .

4. The composition of claim 2, wherein the peptide fibril has a molecular weight of at least 10,000 da – 7×10^8 da.

5. The composition of claim 2, wherein the self-assembling peptide comprises an amino acid sequence of QQKFQFQFEQQ; KFQFQFE; QQRQFQFQFEQQ; QQRQFQWQFEQQ; FEFQFKFKFEFQFKFK; QQRFEWEFEQQ; QQXFXWQFQQQ (Where X denotes ornithine); FKFEFKFEFKFE; FKQFKFKQFKFK; AEAKAEAKAEAKAEAK; AEAEAKAKAEAEAKAK; AEAEAEAEAKAKAKAK; RADARADARADARADA; RARADADARARADADA; SGRGYBLGGQGAGAAAAAGGAGQGGYGGGLGSQG; EWEXEXEXEX (Where X = V, A, S, or P); WKXKXKXKXK (Where X = V, A, S, or P); KWVKVKVKVKVKVK (Where X = V, A, S, or P); LLLKKKKKKKKKKLLLL; VKVKVKVKVDPPTKVVKVKVKV; VKVKVKVKVDPPTKVTKVKVKV; KVKVKVKVKDPPSVKVKVKVKV; or VKVKVKVKVDPPSKVVKVKVKV; VKVKVKTKVDPPTKVTKVKVKV.

6. The composition of claim 5, wherein the self-assembling peptide is 6 to 40 amino acids in length.

7. The composition of claim 2, wherein the antigen is covalently coupled to the self-assembling peptide.

8. The composition of claim 7, wherein the antigen is covalently coupled to a terminus of the self-assembling peptide.

9. The composition of claim 8, wherein the antigens are covalently coupled to the carboxy terminus of the self-assembling peptide.

10. The composition of claim 1, wherein the antigen are peptides.

11. The composition of claim 10, wherein the peptides are 5 to 20 amino acids in length.

12. The composition of claim 10, wherein the antigens are T cell and/or B cell epitopes.

13. The composition of claim 1, wherein the antigens are polypeptides.

14. The composition of claim 13, wherein the polypeptides are covalently coupled to the peptide fibril.

15. The composition of claim 14, wherein the polypeptides are covalently coupled to the peptide fibril via a cutinase polypeptide.

16. A self-assembling antigen comprising an antigen coupled to a fibril-forming peptide.

17. A method of inducing an immune response comprising administering an antigenic fibril, comprising a self-assembling peptide coupled to an antigen, in an amount sufficient to induce an immune response.

18. A method of treating a subject having or at risk of developing a microbial infection comprising administering to the subject an effective amount of a composition of claims 1-16.

1/7




FIG. 1




FIG. 2

3/7




FIG. 3




FIG. 4

5/7




FIG. 5

6/7




FIG. 6

7/7




FIG. 7

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/57480

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 47/42 (2011.01)

USPC - 424/278.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 47/42 (2011.01)

USPC: 424/278.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWest, Google Scholar: self-assembl\$4, antigen\$2, peptide\$2, polypeptide\$2, fibril\$2, peptide fibril\$2, vaccine\$2, vaccination\$2, covalent, cutinase, QQKFQFQFEQQ; KFQFQFE; QQRFFQFQFEQQ; QQRFFQWQFEQQ; FEFEFKFKFEFEFKFK; QQRFEWEFEQQ; QQXFXWXFQQQ (Where X denotes ornithine); FKFEFKFEFKFE; FKQFKFQFKFQ; AEAKAEAKAEAKAEAK; AEAEAKAKAEAEAKAK

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BROWN et al., ORAL AVIAN INFLUENZA VACCINE, A Major Qualifying Project Report	1-4, 7-14, 16-18
----	Submitted to the Faculty of the WORCESTER POLYTECHNIC INSTITUTE, [online], 30 Apr	-----
Y	2009, [retrieved on 2011.01.20], Retrieved from the Internet: <URL: http://www.wpi.edu/Pubs/E-project/Available/E-project-050409-144814/unrestricted/MQP_FINAL.pdf	5, 6, 15
Y	US 2007/0190603 A1 (HOLMES et al.) 16 Aug 2007 (16.08.2007); para [0004]-[0005]	5-6
Y	US 2008/0064606 A1 (MRKSICH et al.) 13 Mar 2008 (13.03.2008); para [0088]	15
A	US 2005/0053575 A1 (SOLOMON) 10 Mar 2005 (10.03.2005); para [0059]	13-15
A	US 7,056,510 B1 (CHOI et al.) 06 Jun 2006 (06.06.2006); abstract; col 1, ln 10-19	14, 15

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 January 2011 (22.01.2011)

Date of mailing of the international search report

04 FEB 2011

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774